# Verrica to Participate in the Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/VRCA/verrica-to-participate-in-the-jefferies-global-healthcare-conference
Ticker: VRCA
Company: Verrica Pharmaceuticals
Source: Verrica Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://verrica.com
## Summary

WEST CHESTER, PA – May 28, 2026 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological ...

## Article Body
WEST CHESTER, PA – May 28, 2026 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.

Jefferies Global Healthcare Conference, June 2-4, 2026

Event details :

Date: Thursday, June 4, 2026

Time: 11:05am ET

Location: New York

Participants may access a live webcast of the event by clicking the link here .

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com . A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com .
## Recent Company News
- 2026-06-25 13:46 EST — [Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal-clinical-trial-cove-3-of-its-phase-3-program-evaluating-ycanthr-vp-102-for-the-treatment-of-common-warts) — Source: Verrica Pharmaceuticals
- 2026-06-25 13:46 EST — [Verrica to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/VRCA/verrica-to-participate-in-the-jefferies-global-healthcare-conference) — Source: Verrica Pharmaceuticals
- 2026-06-25 13:46 EST — [Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq) — Source: Verrica Pharmaceuticals
- 2026-06-25 13:46 EST — [Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2026-financial-results) — Source: Verrica Pharmaceuticals
- 2026-06-25 13:46 EST — [Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-first-patient-dosed-in-phase-3-program-evaluating-ycanthr-vp-102-for-the-treatment-of-common-warts) — Source: Verrica Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)